Regorafenib targets multiple receptor tyrosine kinases, including those involved in tumor angiogenesis (VEGFR-1, -2, -3, endothelial-specific receptor tyrosine kinase 2 (TIE2)) and tumor immunity (Colony stimulating factor 1 receptor (CSF1R)) [32]. The gene discussed is FLT1; the disease is neoplasm.